RxDoctor Payments Data

Peter Coelho, MD

Family Medicine · Hollister, CANPI 1285740480

Payments from drug & device makers

$21,923in general payments, 2019–2025

Across 166 payments — averaging $132.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • AbbVie$3K
  • Terumo Medical Corporation$2K
  • GSK$627
  • Novo Nordisk$210
  • Johnson & Johnson$196
  • plus $847 from 18 others

What the payments were for

  • Consulting fees$2,10030%
  • Speaking & faculty fees$2,25032%
  • Food & beverage$2,54937%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,923 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$427,665
Medicare patients
383
Services billed
6,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$174,008
JardianceEmpagliflozin93$142,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$53,830
FarxigaDapagliflozin Propanediol36$53,285
XareltoRivaroxaban28$42,178
MounjaroTirzepatide17$33,609
ProliaDenosumab16$27,877
TrulicityDulaglutide15$26,919
EliquisApixaban21$20,767
JanuviaSitagliptin Phosphate11$17,562
MyrbetriqMirabegron15$11,856
Spiriva RespimatTiotropium Bromide12$11,545
Tresiba Flextouch U-100Insulin Degludec12$9,630
Testosterone40$6,930
Rosuvastatin Calcium323$5,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$210$174,008107 claims
Boehringer IngelheimJardiance, Spiriva Respimat$27$154,538105 claims
Lilly USA, LLCMounjaro, Trulicity$29$60,52932 claims
GSKTrelegy Ellipta$627$53,83067 claims
AstraZenecaFarxiga$15,253$53,28536 claims
Johnson & JohnsonXarelto$196$42,17828 claims
AmgenProlia$61$27,87716 claims
PfizerEliquis, Paxlovid$32$23,62541 claims
MerckJanuvia$11$17,56211 claims
AbbVieSynthroid, Armour Thyroid$2,689$2,81459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Hollister

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →